Antibody–drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody–drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume -, Issue -, Pages 1-11
Publisher
Informa UK Limited
Online
2020-09-28
DOI
10.1080/17512433.2020.1826303
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Tolerability of Antibody-Drug Conjugates in Cancer
- (2019) Anna Wolska-Washer et al. DRUG SAFETY
- Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
- (2019) Franck Morschhauser et al. Lancet Haematology
- Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study
- (2019) Hervé Tilly et al. LANCET ONCOLOGY
- Antibody-drug conjugates- stability and formulation
- (2019) Corinna Duerr et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
- (2019) Bo Yu et al. Journal of Hematology & Oncology
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2019) Jennifer R. Shingleton et al. JOURNAL OF CLINICAL ONCOLOGY
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2019) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody–Drug Conjugates for Cancer Treatment
- (2018) John M. Lambert et al. Annual Review of Medicine
- Resistance to Antibody–Drug Conjugates
- (2018) Sara García-Alonso et al. CANCER RESEARCH
- Investigational Antibody–Drug Conjugates for Treatment of B-lineage Malignancies
- (2018) Alex F. Herrera et al. Clinical Lymphoma Myeloma & Leukemia
- The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates
- (2018) Mark Frigerio et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Fate of Antibody-Drug Conjugates in Cancer Cells
- (2018) Cécile Chalouni et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review
- (2018) Cédric Rossi et al. Targeted Oncology
- Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia
- (2018) Jeffrey Baron et al. Expert Review of Clinical Pharmacology
- Moxetumomab Pasudotox: First Global Approval
- (2018) Sohita Dhillon DRUGS
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies
- (2018) Helen Ma et al. Current Hematologic Malignancy Reports
- Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future
- (2017) Heather E. Vezina et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments
- (2017) Aiko Nagayama et al. Targeted Oncology
- Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- (2016) Ranjana H. Advani et al. CLINICAL CANCER RESEARCH
- New developments for antibody-drug conjugate-based therapeutic approaches
- (2016) Bart ECG de Goeij et al. CURRENT OPINION IN IMMUNOLOGY
- Management of Relapsed Diffuse Large B-cell Lymphoma
- (2016) Michael Crump HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation
- (2016) Qian Gong et al. mAbs
- Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) H. Tilly et al. ANNALS OF ONCOLOGY
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
- (2015) Maria Corinna A Palanca-Wessels et al. LANCET ONCOLOGY
- Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab
- (2013) Luis Fayad et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
- (2010) B. Coiffier et al. BLOOD
- Investigational antibody-drug conjugates for hematological malignancies
- (2010) Andrew G Polson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
- (2009) D. Dornan et al. BLOOD
- Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
- (2009) A. G. Polson et al. CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started